Editorial
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2021; 9(27): 7963-7972
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.7963
Exophiala dermatitidis
Daisuke Usuda, Toshihiro Higashikawa, Yuta Hotchi, Kenki Usami, Shintaro Shimozawa, Shungo Tokunaga, Ippei Osugi, Risa Katou, Sakurako Ito, Toshihiko Yoshizawa, Suguru Asako, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Jiro Oba, Tomohisa Nomura, Manabu Sugita
Daisuke Usuda, Yuta Hotchi, Kenki Usami, Shintaro Shimozawa, Shungo Tokunaga, Ippei Osugi, Risa Katou, Sakurako Ito, Toshihiko Yoshizawa, Suguru Asako, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Jiro Oba, Tomohisa Nomura, Manabu Sugita, Department of Emergency and Critical Care Medicine, Juntendo University Nerima Hospital, Nerima-ku 177-8521, Tokyo, Japan
Toshihiro Higashikawa, Department of Geriatric Medicine, Kanazawa Medical University Himi Municipal Hospital, Himi-shi 935-8531, Toyama-ken, Japan
Author contributions: Usuda D wrote the manuscript; Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokunaga S, Osugi I, Katou R, Ito S, Yoshizawa T, Asako S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Oba J, Nomura T, and Sugita M proofread and revised the manuscript; all authors approved the final version to be published.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daisuke Usuda, MD, MSc, PhD, Doctor, Lecturer, Department of Emergency and Critical Care Medicine, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-ku 177-8521, Tokyo, Japan. d.usuda.qa@juntendo.ac.jp
Received: March 5, 2021
Peer-review started: March 5, 2021
First decision: March 25, 2021
Revised: April 3, 2021
Accepted: August 24, 2021
Article in press: August 24, 2021
Published online: September 26, 2021
Processing time: 195 Days and 1.5 Hours
Abstract

Exophiala is a genus comprising several species of opportunistic black yeasts, which belongs to Ascomycotina. It is a rare cause of fungal infections. However, infections are often chronic and recalcitrant, and while the number of cases is steadily increasing in both immunocompromised and immunocompetent people, detailed knowledge remains scarce regarding infection mechanisms, virulence factors, specific predisposing factors, risk factors, and host response. The most common manifestations of Exophiala infection are skin infections, and the most frequent type of deep infection is pulmonary infection due to inhalation. The invasive disease ranges from cutaneous or subcutaneous infection to systemic dissemination to internal organs. The final identification of the causative organism should be achieved through a combination of several methods, including the newly introduced diagnostic analysis, matrix-assisted laser desorption/ ionization-time-of-flight mass spectrometry, together with sequencing of the ribosomal ribonucleic acid internal transcribed spacer region of the fungi, and histological and culture findings. Regarding treatment, because anti-infective agents and natural compounds exhibited poor antibiofilm activity, few treatments have ultimately been found to be effective for specific antifungal therapy, so the optimal antifungal therapy and duration of therapy for these infections remain unknown. Therefore, most forms of disease caused by Exophiala dermatitidis require aggressive combination therapies: Both surgical intervention and aggressive antifungal therapy with novel compounds and azoles are necessary for effective treatment.

Keywords: Exophiala dermatitidis; Black yeast; Immunocompromised host; Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry; Ribosomal ribonucleic acid; Antifungal drugs

Core Tip: Exophiala is a genus comprising several species of opportunistic black yeasts, which belongs to Ascomycotina, and it is a rare cause of fungal infections. The final identification of this organism should be achieved through a combination of several methods, including the newly introduced diagnostic analysis, matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry, together with sequencing of the ribosomal ribonucleic acid internal transcribed spacer region of the fungi, and histological and culture findings. Most forms of disease caused by this pathogen require aggressive combination therapies: both surgical intervention and aggressive antifungal therapy with novel compounds and azoles are necessary for effective treatment. Today, detailed knowledge regarding this pathogen is scarce, so further studies are required in order to collect evidence.